ClinicalTrials.gg
RecruitingNCT06960564Updated Sep 3, 2026

The Effect of Hyaluronic Acid Injection on TNF-Alpha and IL-1β in Knee Osteoarthritis

An interventional study of Hyaluronic Acid injections and Saline -- placebo comparator in Knee Osteoarthritis and Hyaluronic Acid, sponsored by Istanbul University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Istanbul University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Osteoarthritis, Knee by Istanbul University — 3 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · Istanbul University.

Started
2025
with 1 other
No phase
9 of 11
2 open now
Registered
10th of 11
by date

Among the 11 studies in Osteoarthritis, Knee by Istanbul University, this one is one of 2 that started in 2025, is one of 9 with no phase, and was the 10th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 11 studies in Osteoarthritis, Knee by Istanbul University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Osteoarthritis, Knee by Istanbul University, or all of them as a file.
02

Study summary

In this study, the effect of intra-articular HA injection therapy on pre- and post-treatment TNF-alpha and IL-1beta levels and methylation changes in blood and synovial fluid in patients with knee osteoarthritis will be determined and compared with the placebo group. In addition, the effects of HA injection on pain, functional status and quality of life will be evaluated and these effects will be related to changes in TNF-alpha and IL-1-beta.

03

Conditions studied

  • Knee Osteoarthritis
  • Hyaluronic Acid
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of knee osteoarthritis according to ACR (American College of Rheumatology) criteria
  • Knee pain for more than 3 months
  • Presence of knee pain resistant to conservative treatment for at least 3 months
  • To be between the ages of 45-75
  • Kellgren-Lawrence stage 2-3 gonarthrosis detected in the available knee direct radiographs of the patients

Exclusion criteria

Exclusion Criteria:

  • Patients with KL stage 1 and 4 OA
  • Systematic diseases (severe cardiovascular disease, severe renal failure, severe hepatic failure, uncontrolled diabetes, cancer, , haematological diseases, systemic bone diseases)
  • Bleeding tendency (acquired or inherited) [lNR>2 in a patient on Coumadin],
  • Infection (systemic or local)
  • Secondary knee osteoarthritis (inflammatory joint disease, post-traumatic, post-infectious, etc.)
  • Major knee trauma within the last 1 year
  • >40
  • History of total knee or hip arthroplasty within 1 year
  • Pregnancy
  • History of intra-articular injection within the last 6 months
  • Patients with less than 11 g/dl and Plt less than 150.000
  • Presence of allergy to hyaluronic acid products
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Intra-articular hyaluronic acid injection group

    Device: Hyaluronic Acid injections

  • Placebo comparator
    Intra-articular saline injection group

    Other: Saline -- placebo comparator

Interventions

  • DeviceHyaluronic Acid injections

    Intra-articular hyaluronic acid will be administered to 30 selected patients. Blood and synovial fluid samples will be collected before HA injection and 1 week after 3 sessions of HA injection with one week interval. Home exercise programme will be given.

  • OtherSaline -- placebo comparator

    Intra-articular saline (SF) will be administered to 20 selected patients. Blood and synovial fluid samples will be collected before and 1 week after 3 session of salin injection with one week interval. Home exercise programme will be given.

06

What researchers measure

Primary outcomes

  1. Blood and synovial fluid TNF-alpha levels

    Time frame: Assessments will be made before and 1 week after treatment

  2. Blood and synovial fluid IL-1beta levels

    Time frame: Assessments will be made before and 1 week after treatment

  3. Blood and synovial fluid TNF-alpha methylation changes

    Time frame: Assessments will be made before and 1 week after treatment

  4. Blood and synovial fluid IL-1beta methylation changes

    Time frame: Assessments will be made before and 1 week after treatment

Secondary outcomes

  1. Visual Analogue Scale (VAS)-pain (activity, rest, night)

    minimum value : 0 maximum value :10 Higher scores mean worse outcome.

    Time frame: Evaluations will be performed before and 1 month, 3 months and 6 months after treatment

  2. The Western Ontario and McMaster Universities Arthritis Index (WOMAC)- (pain, stiffness, physical function, total score)

    Minimum value: 0 maximum value : 96 Higher scores mean worse outcome

    Time frame: Evaluations will be performed before and 1 month, 3 months and 6 months after treatment

  3. Lequesne Index (pain or discomfort, walking distance, GYA)

    Minimum value : 0 maximum value: 24 higher scores mean worse outcome.

    Time frame: Evaluations will be performed before and 1 month, 3 months and 6 months after treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2026, 15 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 15 months is below that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 7, 2025
StartActual
May 12, 2025
Primary completionEst.
Sep 2, 2026
CompletionEst.
Sep 2, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06960564
Responsible party
Dicle Rotinda Ozdas Sevgin (Principal Investigator, Istanbul University) — Principal investigator
First posted
May 7, 2025
Start date
May 12, 2025
Primary completion
Sep 2, 2026 (estimated)
Completion
Sep 2, 2026 (estimated)
Last update
Sep 3, 2026

Study contacts

Dicle Rotinda Özdaş Sevgin
Contact
rotindaozdas95@gmail.com
+90 530-141-5940

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion